What the studies show about CJC-1295 in 2026

The strongest human evidence answers a narrow question: how long does the drug last, and which hormones does it raise. Two placebo-controlled studies in 2006 gave healthy adults a single subcutaneous injection, meaning just under the skin ¹. The doses in those studies ranged from 30 to 90 micrograms per kilogram of body weight. Growth hormone rose 2- to 10-fold for at least six days. IGF-1, the liver-made signal that carries much of growth hormone's downstream message, stayed 1.5- to 3-fold higher for nine to eleven days ¹. The half-life, the time the body needs to clear half of a dose, was 5.8 to 8.1 days ¹.

A second 2006 study asked whether days of continuous stimulation would flatten the body's natural growth hormone rhythm. It did not. One week after a 60 to 90 microgram per kilogram dose, the baseline between pulses was 7.5-fold higher and IGF-1 was up 45 percent, but the pulse pattern itself was still present ⁴. In other words, the drug raised the floor between pulses rather than erasing the spikes.

The limitation is that those two trials only tracked hormone readings and short-term tolerability in healthy adults for up to 49 days. They did not measure muscle, recovery, body fat, or performance ¹. Controlled reviews in sports medicine repeat that point: there are no human efficacy trials for those outcomes ².

Animal work shows what the hormone signal can do when the body cannot make its own releasing hormone. Mice bred without growth hormone-releasing hormone, the brain signal that CJC-1295 mimics, were much smaller than normal. Daily dosing with CJC-1295 for five weeks brought body weight, length, lean mass, and fat mass back toward normal ⁵. Dosing every two or three days was not as effective, which fits the idea that regular exposure matters more than occasional spikes ⁵.

A separate mouse model tested the drug in muscle wasting caused by glucocorticoids, a class of steroid medications. When CJC-1295 was combined with ipamorelin, a different drug that triggers growth-hormone release, the maximum force of muscle contraction improved ³. That is a muscle function readout, but it remains an animal result, not human proof.

No controlled human study has tested whether CJC-1295 changes muscle, fat, recovery, sleep, or skin. The published reviews that catalog peptide research state this gap directly ². The only human safety and hormone data come from those two short 2006 trials, and they were not designed to detect those outcomes ¹.

A small human study from 2009 looked at serum protein changes after one dose. It found shifts in a few blood proteins, such as lower apolipoprotein A1 and transthyretin isoforms, and higher albumin and hemoglobin fragments ⁶. The meaning of those shifts is unclear, and no later study connected them to any symptom or benefit.

Because the literature is thin, many claims rest on community reports. A 2016 study of online forum posts by women who used CJC-1295 described reports of better sleep, skin, and fat loss ⁷. Those reports are anecdotal, which means they are individual stories collected from forums, not controlled comparisons.

One naming issue adds noise. Some products sold as CJC-1295 are actually a short-acting version without the long-lasting albumin-binding tail, a different product with a different schedule ⁸. That confusion makes it hard to know which compound any community report describes.

CJC-1295 is not approved by the US Food and Drug Administration for any medical use, and the reviews that cover its legal status report no marketing authorization in any major jurisdiction ⁹. It circulates through gray-market channels as a research compound, a label that carries no requirement to prove safety or effectiveness ⁹. In sport, it is prohibited at all times under the World Anti-Doping Agency's list of peptide hormones and growth factors ¹⁰.

The product itself is a measurable risk. When researchers tested 6,441 consumer-marketed peptide samples, including CJC-1295, 41.6 to 71.1 percent failed basic purity or abundance checks, and 15 percent had measurable endotoxin, a bacterial contaminant ¹². That means a bad reaction after a new vial may come from what is in the vial, not from the peptide alone.

Long-term class cautions come from growth hormone-axis drugs in general, not from CJC-1295 human trials specifically. Those cautions include fluid retention, joint aches, changes in blood sugar, and a biologically plausible but unproven concern about chronically raised IGF-1 and cell growth ⁸. The related oral compound MK-677 has been linked to congestive heart failure in a sports medicine review, and that caution is often carried over to the broader class ¹¹.

The main gap is outcome evidence in humans. No controlled study has followed people using CJC-1295 for months and compared muscle, fat, recovery, or sleep against placebo. The longest controlled human exposure was 49 days, and it only tracked hormones and basic safety ¹.

It is also not known whether the pituitary gland adapts or desensitizes over longer cycles. The short trials saw a cumulative IGF-1 effect with repeat dosing rather than a fading response, but no human study looked beyond seven weeks ¹. How the body responds after months remains untested.

The purity data leave another open question: how many reported effects come from the actual peptide rather than contaminants or mislabeled products ¹². Until those gaps are filled, the evidence supports one statement: the hormone rise is real and long-lasting, but the human benefit has not been shown.